SILO Silo Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1514183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY26.7%
TTM EPS YoY159.8%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,534.1%
Net margin-10,319.0%
FCF margin—
EBITDA margin—
Returns
ROE-55.3%
ROA-49.0%
ROIC (approx.)-207.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.0%
Debt / equity0.00x
Current ratio24.43x
Interest coverage-112.82x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $18,026 | $18,026 | $18,025 | $18,025 | $18,026 | $18,026 |
| Cost of revenue | — | $0 | $20,688 | $20,689 | $20,687 | $1,459 | $1,460 | $1,460 |
| Gross profit | — | $0 | -$2,662 | -$2,663 | -$2,662 | $16,566 | $16,566 | $16,566 |
| R&D expense | $559,091 | $298,418 | $1.01M | $306,005 | $543,615 | $717,247 | $593,962 | $1.08M |
| Operating income | -$1.21M | -$928,949 | -$1.59M | -$786,524 | -$1.15M | -$1.25M | -$1.09M | -$1.81M |
| Interest expense | $1,114 | $2,865 | $3,373 | $32,702 | $886 | $1,648 | $2,066 | $274 |
| Pretax income | -$358,743 | -$832,829 | -$1.65M | -$881,530 | -$1.11M | -$1.20M | -$1.03M | -$1.73M |
| Net income | -$358,743 | -$832,829 | -$1.65M | -$881,530 | -$1.11M | -$1.20M | -$1.03M | -$1.73M |
| EPS (basic) | -0.21 | -0.76 | -0.12 | — | -1.79 | -2.88 | -0.23 | — |
| EPS (diluted) | -0.21 | -0.76 | -0.12 | — | -1.79 | -2.88 | -0.23 | — |
| Weighted avg. shares (diluted) | 1.75M | 1.10M | 13.71M | — | 622,090 | 418,649 | 4.48M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.09M | $3.28M | $3.90M | $4.75M | $3.92M | $4.33M | $3.14M | $3.91M |
| Short-term investments | $1.96M | $1.95M | $2.13M | $2.11M | $1.95M | $1.93M | $2.31M | $3.17M |
| Current assets | $8.59M | $5.71M | $6.80M | $7.39M | $6.16M | $6.37M | $5.60M | $7.11M |
| Intangibles | $208,562 | $211,500 | $214,438 | $217,375 | $220,312 | $223,250 | $238,123 | $241,215 |
| Total assets | $8.80M | $5.95M | $7.02M | $7.61M | $6.38M | $6.65M | $5.90M | $7.41M |
| Current liabilities | $351,453 | $1.07M | $704,845 | $650,183 | $708,339 | $1.05M | $1.19M | $1.66M |
| Total liabilities | $351,453 | $1.07M | $1.34M | $1.30M | $1.38M | $1.74M | $1.89M | $2.38M |
| Shareholders' equity | $8.44M | $4.89M | $5.68M | $6.31M | $5.01M | $4.92M | $4.01M | $5.03M |
| Shares outstanding | 1.89M | 1.13M | 16.27M | 887,886 | 10.46M | 8.65M | 4.48M | 4.48M |
| Cash flow statement | ||||||||
| Operating cash flow | -$603,534 | -$781,861 | -$822,623 | -$780,278 | -$955,493 | -$1.29M | -$1.64M | -$917,432 |
| Investing cash flow | -$17,337 | $183,439 | -$23,563 | -$519,988 | -$95,474 | $388,102 | $871,381 | -$37,659 |
| Financing cash flow | $3.43M | — | — | $2.13M | $634,922 | — | — | $0 |
| Stock-based compensation | $9,352 | $39,174 | $56,619 | $52,309 | $47,267 | -$161,024 | $178,469 | $395,310 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.